Following is a brief extract from today's release that has also encouraged me to take a small start up position.

ASX ANNOUNCEMENT:

14 March 2022 Leadless Pacemakers included in SOLVE-CRT IDE Clinical Trial Key Highlights:

The US FDA (Food & Drug Administration) has agreed for EBR to include leadless (wireless) pacemakers as a co-implant in the pivotal SOLVE-CRT IDE clinical trial

If approved for final labelling during the PMA application, the opportunity to pair leadless pacemakers with the WiSE® CRT System to deliver cardiac resynchronisation therapy (CRT) potentially expands EBR’s initial addressable market by US$400m in 2024

SOLVE-CRT remains on track to complete enrolment for interim analysis by H1 2022 

US FDA approves EBR’s wireless pacemakers: